More than 1,000 participants received free screenings for blood pressure, cholesterol, triglycerides, body mass index, and peripheral vascular disease at heart-health fairs sponsored by the Mount Sinai Health System on Friday, February 6, National Go Red for Women Day. Read more
Heart disease, stroke, and cardiovascular diseases are the number one cause of death in women. While awareness has doubled over the last 15 years, still only 56 percent of women identified heart disease as the leading cause of death in a 2012 survey by the American Heart Association.
One in three women dies from heart attack and stroke, but many of these deaths can be prevented. Women often come to the emergency room too late because they attributed their symptoms to less life-threatening conditions like acid reflux or the flu.
Sean Pinney, MD, is Director of the Advanced Heart Failure and Transplantation Program at The Mount Sinai Hospital. He shared his answers to some of the most frequently asked questions of heart failure patients.
1. My health practitioner thinks I may have heart failure. Why did my health practitioner order so many different tests? Read more
HCM causes symptoms of dyspnea or shortness of breath, chest pain, exercise intolerance, syncope or fainting, and uncommonly, sudden cardiac death (SCD). It affects individuals of all ages but most commonly presents after age 30. Many patients with HCM have a relatively benign course and can have normal life expectancy, and symptoms can be managed with first-line pharmacologic agents like beta blockers or verapamil. However, a quarter of patients will experience in their course either severe disabling symptoms or SCD. Read more
A USA Today article noted “The Medicare metric for timely heart attack treatment is … “door-to-balloon” time — the time between when a heart attack patient arrives in the ER and when the balloon angiography begins — researchers found that the percentage of heart attack patients who die while in the hospital, about 5%, hasn’t changed.”
“Irreversible damage from a heart attack can begin in 30 minutes. Most tissue death occurs in the first two to three hours…” “A new study suggests that speeding up hospital care isn’t enough to save lives … A better predictor of survival might be ‘symptom to balloon time’…”
In a groundbreaking, multi-centered randomized trial published in The New England Journal of Medicine, researchers, co-led by Mount Sinai’s David H. Adams, MD, determined that a catheter-based heart procedure to replace an aortic valve was superior to surgery for patients who have symptomatic severe aortic stenosis with increased risks. The findings, based on a clinical trial involving 795 patients treated at 45 institutions across the nation, were simultaneously presented by Dr. Adams at the 63rd Annual Scientific Session of the American College of Cardiology on Saturday, March 29, and represent a major advance for heart patients who are at high risk for surgery.
An injectable nanoparticle that delivers HMG-CoA reductase inhibitors, or statins, which directly inhibit atherosclerotic plaque inflammation could represent a new frontier in the treatment of heart disease. This novel approach is being developed by researchers at Icahn School of Medicine at Mount Sinai, who have seen promising results in mice models and plan to translate their findings to humans within the next few years.
The Mount Sinai Hospital Cardiac Care Unit (CCU) was awarded a 2014 Beacon Award for Excellence from the American Association of Critical-Care Nurses (AACN), the leading society of acute- and critical-care nurses.
The Mount Sinai Hospital is one of three institutions in New York State, and one of one hundred in the nation, selected to study the safety and effectiveness of an implantable cranial nerve stimulation device for heart failure patients with debilitating fatigue, shortness of breath, and heart arrhythmias.
Mitral Valve Prolapse (MVP) is a common heart valve abnormality that affects up to 5 percent of the U.S. population. The mitral valve controls the flow of blood from the lungs to the main pumping chamber of the heart. MVP results from a degeneration of valve structure that leads to a regurgitation of blood backwards that can result in heart enlargement and weakening, as well as fatigue and shortness of breath.